Oncology

Filter

Patient discussing breast cancer quality of life and weight loss intervention with oncology clinician.

ASCO 2026: Weight Loss Intervention Boosts Breast Cancer QoL

June 2026

Weight loss intervention improved breast cancer quality of life and symptoms in BWEL results presented at ASCO 2026.

Patient discussing breast cancer quality of life and weight loss intervention with oncology clinician.

ASCO 2026: Weight Loss Intervention Boosts Breast Cancer QoL

Weight loss intervention improved breast cancer quality of life and symptoms in BWEL results presented at ASCO 2026.

Physician reviewing localized prostate cancer treatment outcomes and healthcare costs with a patient.

High-Risk Prostate Cancer Drives Poorer Outcomes And Higher Costs

Localized prostate cancer risk stratification predicted poorer survival and higher healthcare costs after radical prostatectomy.

Hospitalist and oncology clinician discussing inpatient cancer care gaps in a hospital setting

Inpatient Oncology Care Needs Stronger Collaboration

Onco-hospitalist programs may close key inpatient oncology care gaps in communication, collaboration, training, and cancer management.

Clinician discussing darolutamide cognitive decline data with a patient with prostate cancer.

ASCO 2026: Darolutamide Shows Cognitive Edge in Prostate Cancer

Darolutamide showed less cognitive decline than enzalutamide in ARACOG results presented at ASCO 2026 for prostate cancer.

Patient consulting oncologist about head and neck cancer treatment options.

ASCO 2026: New First-Line Option Emerges in Head and Neck Cancer

Head and neck cancer survival improved with TMC-I versus platinum chemotherapy in recurrent or metastatic disease.

Contrast-enhanced mammography equipment used to assess breast cancer response after neoadjuvant therapy.

Can Contrast-Enhanced Mammography Rival MRI in Breast Cancer Care?

Contrast-enhanced mammography showed good accuracy for assessing breast cancer response after neoadjuvant therapy in pooled data.

Doctor discussing TALAPRO-3 prostate cancer treatment options with a patient.

ASCO 2026: TALAPRO-3 Delays Prostate Cancer Progression

TALAPRO-3 data show talazoparib plus enzalutamide delayed progression in HRR-deficient metastatic castration-sensitive prostate cancer.

Oncology clinician reviewing SUCCESSOR-2 multiple myeloma treatment data with a patient

ASCO 2026: SUCCESSOR-2 Advances Relapsed Myeloma Treatment

SUCCESSOR-2 data showed MeziKd prolonged progression-free survival in relapsed or refractory multiple myeloma at ASCO 2026.

Loading posts...

1 2 3 … 40 Next »